// App-Quantinova.ai

AB0884 (2022) : Disease outcomes in patients with psoriatic arthritis completing 12 months of apremilast treatment - Real-world data from the REWARD study

Researchers

Presenter

  • R. Bos

Principal Investigators

  • T. Jansen

  • I. Bridges

  • S. De Jong

  • M. Vis

Medical Centers

  • MCL, Rheumatology, Leeuwarden, Netherlands

  • Viecurie MC, Rheumatology, Venlo, Netherlands

  • Amgen, Biostatistics, Uxbridge, United Kingdom

  • Breda, Medical, Breda, Netherlands

  • Erasmus, rheumatology, Rotterdam, Netherlands

Locations

  • Netherlands

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Musculoskeletal

  • Dermatology

Disease

  • Psoriatic arthritis

Biomarkers

  • N/A

Drug/Treatment

  • Apremilast

Outcome

  • N/A

Study Design

  • N/A

Phase

  • N/A

Study Id's

  • N/A

Sponsors

  • Galapagos NV

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved